Immutep S.A. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 34

Immutep S.A. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Immutep S.A. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Immutep S.A. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immutep S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immutep S.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immutep S.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Immutep S.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immutep S.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immutep S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immutep S.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immutep S.A. and identify potential opportunities in those areas.

List of Tables
List of Figures
Immutep S.A. Snapshot
Immutep S.A. Overview
Key Information
Key Facts
Immutep S.A. – Research and Development Overview
Key Therapeutic Areas
Immutep S.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Immutep S.A. – Pipeline Products Glance
Immutep S.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Immutep S.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Immutep S.A. – Drug Profiles
ImmuFact IMP321
Product Description
Mechanism of Action
R&D Progress
ImmuFact IMP321 + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
ImmuFact IMP321 Chemo-Immunotherapy
Product Description
Mechanism of Action
R&D Progress
IMP701
Product Description
Mechanism of Action
R&D Progress
IMP731
Product Description
Mechanism of Action
R&D Progress
Immutep S.A. – Pipeline Analysis
Immutep S.A. – Pipeline Products by Therapeutic Class
Immutep S.A. Pipeline Products By Target
Immutep S.A. – Pipeline Products by Route of Administration
Immutep S.A. – Pipeline Products by Molecule Type
Immutep S.A. – Recent Pipeline Updates
Immutep S.A. - Dormant Projects
Immutep S.A. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 07, 2010: Immutep Announces Final Results From Phase I/II Chemoimmunotherapy Trial In Metastatic Breast Cancer
May 01, 2010: Immutep Announces Oral Presentation At ASCO Annual Meeting Of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Jan 04, 2010: Immutep Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer For ImmuFact IMP321
Jan 01, 2010: ImmuFact IMP321 Doubles Clinical Response Rate In First-Line Metastatic Breast Cancer
Jan 01, 2010: ImmuFact IMP321 Doubles Clinical Response Rate In First-Line Metastatic Breast Cancer
Jan 01, 2010: ImmuFact IMP321 Doubles Clinical Response Rate In First-Line Metastatic Breast Cancer
Oct 31, 2009: Immutep Announces That ImmuFact IMP321 Doubles Clinical Response Rate
Oct 01, 2009: New Results Confirm That ImmuFact IMP321 Doubles Clinical Response Rate
Sep 29, 2009: Immutep Announces Final Results In Advanced Renal Cell Carcinoma Drug, ImmuFact IMP321
Sep 29, 2009: Clinical Research Paper Describes IMP321’s Potency In Inducing Progression-Free Survival Improvement And Effector Memory T Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Spain Defense Industry - Competitive Landscape and Strategic Insights to 2017: Market Profile
• Aerospace and Defense Industry - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• The Greece Defense Industry - Competitive Landscape and Strategic Insights to 2017: Market Profile
• Sports and Fitness Nutrition - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Charter Schools - Global Outlook
• Defense Expenditure in Romania to 2015 - Industry Dynamics and Competitive Landscape: Market Profile
• The Romanian Defense Industry to 2015 - Competitive Landscape and Strategic Insights
• The Romania Defense Industry - Competitive Landscape and Strategic Insights to 2016: Market Profile